EGFR and non-small cell lung carcinoma: This combined therapy exhibits a higher therapeutic effect in vivo compared to single-drug therapy, suggesting a feasible strategy to overcome drug resistance of NSCLC to EGFR-TKI (Tong et al., 2019).